Read up on essential news

We want to keep you informed. Here are a few important news items and reminders for you this month:

- Paperless EOB statements
- Changes to our National Precertification List (NPL)
- Third Party Claim and Code Review Program
- Effective-date change for technical-component-only codes
- Cystic fibrosis panel screening

We’re going paperless! Here’s how to get electronic EOB statements and payments

Starting in September 2021 through 2022, we’re phasing out paper Explanation of Benefits (EOB) statements and checks. Sign up before it’s your turn. If you don’t enroll to receive direct deposit payments, you may receive future payments by virtual credit card. Keep reading to learn more.

Get EOB statements from Availity®
Register for our Availity provider portal. Get identical copies of your EOB statements from the Availity Remittance Viewer. Then print or save them to your computer. You won’t need to wait for them to arrive in the mail.

Sign up for direct deposit payments
Sign up for direct deposit payments at Payer Enroll Services. We stopped using EnrollHub® effective September 1. Even if you’re already enrolled to receive direct deposit payments (or electronic remittance advice), use the new portal to make changes.

Visit AetnaPaperlessOffice to learn more about your options.
Changes to our National Precertification List (NPL)

The following new-to-market drugs require precertification

- **Nexviazyme™** (avalglucosidase alfa-ngpt) — precertification required for both the drug and site of care, effective October 7, 2021. This drug is part of the Enzyme Replacement Drugs category.
- **Saphnelo™** (anifrolumab-fnia) — precertification required for both the drug and site of care, effective October 7, 2021.

Submitting precertification requests

Be sure to submit precertification requests at least two weeks in advance.

To save time, request precertification online. Doing so is fast, secure and simple. You can submit most requests online through our [Availity provider portal](#). Or you can use your practice’s Electronic Medical Record (EMR) system if it’s set up for electronic precertification requests.

Are you asking for precertification on a specialty drug for a commercial or Medicare member? Then submit your request through Novologix®, also available on Availity®.

**Not registered for Availity?**

Go to Availity to register and learn more. Please use our “Search by CPT code” search function on our [precertification lists page](#) to find out if the code requires precertification.

[Learn more about precertification.](#)

Third Party Claim and Code Review Program

Beginning November 15, 2021, you may see new claim edits applying to our Student Health plans. These edits are part of our Third Party Claim and Code Review Program. These edits support our continuing effort to process claims accurately for our commercial and Medicare members, and now include student health plans. You can view these edits on our [Availity provider portal](#). You’ll need to know your Aetna® provider ID number (PIN) to use the portal.

For all coding changes, go to:
We may request medical records for certain claims, such as high-dollar claims, implant claims and bundled-services claims, to help confirm coding accuracy.

For our commercial and Medicare plans, you’ll also have access to our prospective claims editing disclosure tool.

**Effective-date change for technical-component-only codes**

We will no longer reimburse for professional services performed in a hospital setting for technical-only procedure codes. The Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule lists these codes as diagnostic only, and they do not have a related professional code.

In June, we told you these edits would be effective in September. These updates have been delayed and will now become effective November 1, 2021.

**Cystic fibrosis panel screening**

Aetna considers a core panel of 25 mutations recommended by the American College of Medical Genetics (ACMG) to be medically necessary for cystic fibrosis genetic testing. Screening for cystic fibrosis mutations that extend beyond the standard mutation panel recommended by the ACMG is considered experimental and investigational.

In addition, Multigene Panels to predict the risk of several inherited disorders, including but not limited to hereditary cancer panels (e.g., BreastNext; CancerNext; CancerNext Expanded; ColoNext; Coloseq; Invitae Common Hereditary Cancers Panel; Invitae Gastric Cancer Panel; Invitae Hereditary Cancer Syndromes Panel; Invitae Hereditary Paraganglioma-Pheochromocytoma Panel; Invitae Melanoma Panel; Invitae Melanoma-Pancreatic Cancer Panel; Invitae Multi-Cancer Panel; Invitae Pancreatic Cancer Panel; Invitae Thyroid Cancer Panel; myRisk Hereditary Cancer Panel; OncoGeneDx Comprehensive Cancer Panel; OncoGeneDx Custom Panel; OncoGeneDx High/Moderate Risk Panel; OncoGeneDx Pancreatic Cancer Panel; OvaNext; PancNext; Panexia; and VistaSeq Hereditary Cancer Panel) and expanded/pan-ethnic carrier screening panels (e.g., Preparent, GeneVu, and CarrierMap), are considered experimental and investigational.
See our [Clinical Policy Bulletin 0140-Genetic Testing](#).